Please login to the form below
drug pricing
This page shows the latest drug pricing news and features for those working in and with pharma, biotech and healthcare.
Pfizer, Sanofi and others set to increase US drug prices in 2021
Drug pricing will also be a focus of the incoming President-elect, Joe Biden, who has promised to reduce drug prices in the US. ... One key tenet of Biden’s drug pricing pledge is to allow Medicare to negotiate drug prices directly with pharma companies
Latest news
-
Moderna looks to price COVID-19 vaccine at $50-$60 per course
Shines spotlight on pricing strategies for potential vaccines. COVID-19 vaccine frontrunner Moderna is allegedly looking to price its candidate at around $50-$60 per course, according to a report from ... According to the report, Moderna’s proposed
-
Lilly joins new Medicare scheme to reduce insulin prices
of-pocket drug costs.
-
FDA clears generic of Daraprim, the ‘poster drug’ for price-gouging
Phoenixus has resisted pressure to lower the price of the drug, and is reportedly haemorrhaging cash – a situation which will presumably only get worse once the generic is available. ... Gaming tactics include preventing generic drugmakers getting
-
Ex-Sandoz exec admits role in generic drug price-fixing plot
The two named products are clobetasol, an eczema and psoriasis treatment, and nystatin triamcinolone, an anti-fungal drug that also has a corticosteroid. ... Drug pricing is a particularly hot-topic among US politicians at the moment, and has snowballed
-
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price
GENEr8-1 trial of the drug – enough to meet the pre-specified criteria for regulatory review. ... The uncertainty of the durability of BioMarin’s drug has left space for other haemophilia A hopefuls from rival developers.
Moderna looks to price COVID-19 vaccine at $50-$60 per course
Lilly joins new Medicare scheme to reduce insulin prices
FDA clears generic of Daraprim, the ‘poster drug’ for price-gouging
Ex-Sandoz exec admits role in generic drug price-fixing plot
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price
More from news
Approximately 72 fully matching, plus 197 partially matching documents found.
Latest Intelligence
-
Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world
While certain stigmas about Big Pharma exist (eg, drug pricing), the companies’ names are well known and generally trusted by HCPs and consumers.
-
The search for effective drug treatments for COVID-19
What are the specific challenges of getting scientific consensus during a rapidly developing drug process in the midst of a global pandemic? ... How does pricing for the drug in the EU compare to pricing in the US?
-
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski. Eliminating pharmacy benefit manager (PBM) rebates has been proposed to address several healthcare issues associated with pharmaceutical pricing (eg, increasing patient prescription drug costs) but ... Due to
-
The impact of COVID-19 on clinical trials
Based on our discussions with venture capitalists, many anticipate potentially severe cash flow issues for drug developers. ... The impact of the pandemic on clinical trials is likely to be felt on a policy level, including in drug pricing negotiations.
-
Health trust in a COVID-19 world – a unique opportunity for pharma
Our team there hypothesised that this may be due to several highly publicised issues including Servier’s long-awaited trial over the safety of a weight loss drug, a large, monthslong ... hospital strike, increasing anti-vaccination sentiment and
Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world
The search for effective drug treatments for COVID-19
Eliminating pharmaceutical rebates, is this déjà vu?
The impact of COVID-19 on clinical trials
Health trust in a COVID-19 world – a unique opportunity for pharma
More from intelligence
Approximately 7 fully matching, plus 40 partially matching documents found.
Latest appointments
-
New faces at Lucid Group and ZPB Associates
Most recently, she worked in the consultancy’s rare diseases division, where is provided crisis management support in pricing/access barriers for an orphan drug.
-
Pfizer’s Emms takes up ABPI presidency
Emms is no stranger to these issues, having served on the ABPI board and taken part in the negotiations over the future of drug pricing in the UK. ... He has not been afraid to criticise the outcomes of these discussions too, saying in November that the
-
Bayer's Martin Hesse moves to Daiichi Sankyo Europe
Commenting on the environment in which he starts at Daiichi, Hesse said securing the company's profitability and competitiveness in the light of drug pricing interventions will a major challenge.
New faces at Lucid Group and ZPB Associates
Pfizer’s Emms takes up ABPI presidency
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era
drug pricing?”. ... current barriers to progress in this area include perverse financial incentives, separation of hospital and drug budgets and inefficiencies within the system.
-
OPEN Health
Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era. ... drug pricing?”.
-
Pricing's Point Man
In the wake of the publication of the second edition of 'The Price of Global Health', Ed Schoonveld talks to William Looney. Pharm Exec Editor-in-Chief William Looney talks to Ed Schoonveld about the key policy and management issues around market
-
Turkey: Identifying the Growth Drivers
This sector is dominated by pro-innovative drug prescribing physicians as well as a patient population who is willing to pay for a higher “quality” healthcare. ... Overall, while the public sector is characterised today byaggressive drug pricing
-
Article: The Colombia Conundrum
drug pricing, as well as a streamlining of the essential drug list to remove some of the higher cost drugs. In a move to combat corruption, the EPS are set to ... This is exemplified by Sanofi’s 2012 acquisition of Genfar, which has resulted in the
OPEN Health
More from PMHub
Approximately 3 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital account director
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
-
Digital project manager
-
Competitive
-
Events Executive
-
Depending on Experience
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- GSK reveals plans for £400m R&D facility expansion in England
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- AZ’s PNH therapy Ultomiris wins EU backing to expand use for children
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Straight outta lockdown – what’s next for flexible working?
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
No results were found
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
